Health Affairs March 24, 2023
Troyen A. Brennan

The high price of medications is driving many different policy initiatives aimed at providing relief for patients and health care payers. The Inflation Reduction Act is the most comprehensive example, as the federal government commences negotiation of prices with manufacturers for a limited number of medications. Other proposals are more focused, such as the cap on out-of-pocket spending for patients with diabetes in the Medicare Part D program who must purchase insulin. In the same vein, the state of California has recently sued insulin producers and pharmacy benefit managers, alleging unsound business practices and seeking relief for patients unable to afford insulin. Many other beneficiaries and payers are now getting relief from high prices through the so-called 340B program, which...

Today's Sponsors

Upfront Healthcare

Today's Sponsor


Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
Acquisition and Investment Spur AVEO Oncology to New Heights
'The Top Line': The 20 most influential people in biopharma, plus this week's headlines
6 ways to build a pharmaceutical culture centered on patient safety
AI in drug development: A reality check
This Panel Will Decide Whose Medicine to Make Affordable. Its Choice Will Be Tricky.

Share This Article